FDA Warns Novo Nordisk Over Unreported Deaths and Strokes in GLP-1 Users

The FDA has issued a warning letter to Novo Nordisk for failing to properly report deaths and strokes among patients taking its GLP-1 medications, including the blockbuster drugs Ozempic and Wegovy. The letter, dated March 5 and released publicly Tuesday, accuses the Danish pharmaceutical giant of systematic failures in its safety reporting obligations.

According to MedPage Today, the FDA found that Novo Nordisk failed to investigate and report potentially serious adverse events within required timeframes. The agency's warning specifically cited instances where the company did not adequately follow up on reports of deaths and cardiovascular events, including strokes, in patients using semaglutide-based medications.

The warning letter represents one of the FDA's most serious regulatory actions short of legal enforcement. It signals that the agency believes Novo Nordisk's safety reporting system falls below federal standards designed to protect patients and inform healthcare providers about medication risks.

Novo Nordisk's GLP-1 medications have generated over $21 billion in annual revenue, with millions of patients worldwide using semaglutide for diabetes management and weight loss. The drugs work by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to reduced appetite and significant weight loss in many users.

Safety reporting requirements exist to ensure that patterns of serious side effects are quickly identified and communicated to doctors and patients. When pharmaceutical companies fail to report adverse events promptly, it can delay important safety updates or label changes that might prevent harm to other patients.

The FDA's action comes amid ongoing scrutiny of GLP-1 medications' side effect profiles. While these drugs are generally considered safe and effective, they carry known risks including pancreatitis, gallbladder problems, and potential thyroid tumors. Cardiovascular outcomes have been a particular focus of research, with some studies showing protective effects against heart disease, while individual cases of serious cardiovascular events continue to be reported.

Novo Nordisk now has 15 business days to respond to the FDA with a detailed plan for correcting its reporting deficiencies. The company must also conduct a comprehensive review of its adverse event reporting system and implement new procedures to ensure compliance with federal safety requirements.

What This Means for Patients

For current users of Ozempic, Wegovy, or Rybelsus, this warning does not indicate any immediate change to the known safety profile of these medications. The issue lies with reporting procedures, not newly discovered risks. However, patients should remain vigilant about potential side effects and report any concerning symptoms to their healthcare providers promptly.

Those considering starting GLP-1 therapy should discuss cardiovascular risk factors with their doctors, particularly if they have a history of heart disease or stroke. The FDA's action underscores the importance of robust safety monitoring systems, but does not alter the established benefits and risks that should guide treatment decisions.